Top Markets
#1 Ontology Gas Ontology Gas +30.80%
#2 EXOD EXOD +22.08%
#3 Status Status +21.90%
#4 ETHGas ETHGas +19.74%
#5 The Black Bull The Black Bull +17.98%
#6 Anvil Anvil +12.83%
#7 Fake World Assets Fake World Assets +10.94%
#8 aelf aelf +9.61%
#9 Gas Gas +9.27%
#10 Derive Derive +8.79%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rank in Stocks #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Share Price
$9.81
Last synced: 2025-03-18
Market Cap
$48.68M
Change (1 day)
1.55%
Change (1 year)
0.00%
Country
US
Trade AlloVir, Inc. (ALVR)

Category

Healthcare
Earnings for AlloVir, Inc. (ALVR)
Earnings in Jun 2026 TTM: $-54.46M
According to AlloVir, Inc. latest financial reports the company's current earnings are $-54.46M. In 2023 the company made an earning of $-190.54M, a decrease compared to its 2022 earnings that were of $-168.98M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AlloVir, Inc. from 2018 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-54.46M -7.33%
2024 $-58.77M -69.16%
2023 $-190.54M 12.76%
2022 $-168.98M -1.16%
2021 $-170.96M 144.98%
2020 $-69.78M 192.73%
2019 $-23.84M 881.03%
2018 $-2.43M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -9,786.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,681.87%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -3,064.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 5,568.48%
US